D-丝氨酸联合听觉认知矫正治疗精神分裂症的剂量依赖性神经可塑性增强:一项双盲、安慰剂对照、随机、靶点 engagement 临床试验
BACKGROUND: Patients with schizophrenia show reduced NMDA glutamate receptor-dependent auditory plasticity, which is rate limiting for auditory cognitive remediation (AudRem).…
核心结论
- 结果证明D-丝氨酸联合AudRem组合及靶点 engagement 方法学具有充分原理验证,值得继续开发。
- 最终效用取决于正在进行的一项更大规模、更长疗程研究对临床相关结局的结果。
研究设计与样本
- 随机接受3次每周一次AudRem联合双盲D-丝氨酸(80、100或120 mg/kg)或安慰剂,分3个剂量队列,每队列12例D-丝氨酸和3例安慰剂。
- AudRem任务为判断配对音调中哪个音高更高。
- 主要结局为可塑性改善,即AudRem音调间音高阈值变化,从初始平台期音高阈值(治疗第1次访视第20-30试次均值)至访视结束时音高阈值。
- 靶点 engagement 通过脑电图结局评估,包括失匹配负波(MMN,音高为主要指标)。
主要发现
- 可塑性改善在单次治疗后即出现,并在后续治疗中持续。
临床怎么用
- 提示D-丝氨酸联合听觉认知矫正可能剂量依赖性地增强精神分裂症患者的神经可塑性,80-100 mg/kg范围值得进一步研究。
- 行为与脑电图 pharmacodynamic 靶点 engagement 生物标志物可用于后续药物开发中的早期疗效信号检测。
局限性
- 临床相关结局的效用尚待正在进行的大型长疗程研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with schizophrenia show reduced NMDA glutamate receptor-dependent auditory plasticity, which is rate limiting for auditory cognitive remediation (AudRem). We evaluate the utility of behavioral and neurophysiological pharmacodynamic target engagement biomarkers, using a d-serine+AudRem combination. METHODS: Forty-five participants with schizophrenia or schizoaffective disorder were randomized to 3 once-weekly AudRem visits + double-blind d-serine (80, 100, or 120 mg/kg) or placebo in 3 dose cohorts of 12 d-serine and 3 placebo-treated participants each. In AudRem, participants indicated which paired tone was higher in pitch. The primary outcome was plasticity improvement, operationalized as change in pitch threshold between AudRem tones [(test tone Hz - reference tone Hz)/reference tone Hz] between the initial plateau pitch threshold (mean of trials 20-30 of treatment visit 1) to pitch threshold at the end of visit(s). Target engagement was assessed by electroencephalography outcomes, including mismatch negativity (pitch primary). RESULTS: There was a significant overall treatment effect for plasticity improvement (p = .014). Plasticity improvement was largest within the 80 and 100 mg/kg groups (p < .001, d > 0.67), while 120 mg/kg and placebo-treated participants showed nonsignificant within-group changes. Plasticity improvement was seen after a single treatment and was sustained on subsequent treatments. Target engagement was demonstrated by significantly larger mismatch negativity (p = .049, d = 1.0) for the 100 mg/kg dose versus placebo. CONCLUSIONS: Our results demonstrate sufficient proof of principle for continued development of both the d-serine+AudRem combination and our target engagement methodology. The ultimate utility is dependent on the results of an ongoing larger, longer study of the combination for clinically relevant outcomes.
引用
- Sehatpour P, Iosifescu DV, De Baun HM, et al. Dose-Dependent Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia: A Double-Blind, Placebo-Controlled, Randomized, Target Engagement Clinical Trial of the NMDA Glutamate Receptor Agonist d-serine. Biol Psychiatry. 2023. PMID: 36958998. doi:10.1016/j.biopsych.2023.01.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。